Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ: SSKN) has launched a new business, Home by XTRAC™, providing at-home treatment for skin diseases not eligible for in-office care. This service is insurance-reimbursed and leverages existing resources without significant costs. The company began initial shipments in 2020 and anticipates a positive revenue impact in 2021. The Home by XTRAC™ solution aims to meet the needs of patients with conditions like psoriasis, impacting over 31 million Americans. STRATA expects per patient reimbursements ranging from $1,316 to $5,163.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in medical technology for dermatology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 11 to January 14, 2021. The presentation will be available on demand starting January 11 on the Company’s website. STRATA develops innovative products like the XTRAC excimer laser, targeting dermatologic conditions such as psoriasis and vitiligo, impacting over 35 million Americans. The Company's unique DTC advertising model has expanded its network to over 813 clinics and over 2,000 devices globally, enhancing patient access to treatment.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has renewed its debt through a one-year cash secured loan with Israel Discount Bank of New York at a fixed interest rate of 1.40%, due December 30, 2021. The company focuses on innovative dermatology products, including the XTRAC® excimer laser, used to treat conditions affecting over 35 million patients in the U.S. STRATA has expanded its dermatology partner network to over 813 clinics and maintains a worldwide installed base of over 2,000 devices, employing a direct-to-consumer advertising model.
STRATA Skin Sciences (SSKN) reported Q3 2020 revenue of $5.6 million, a 25% decline from $7.5 million in Q3 2019. Recurring revenue fell 35.9% year-over-year to $3.8 million but saw a 37.2% increase from Q2 2020. Gross margins dropped to 57.5% from 61.8% a year prior. The net loss was $1.3 million, or $0.04 per share, compared to a loss of $0.9 million, or $0.03 per share in Q3 2019. With 837 XTRAC devices installed, the company remains cautiously optimistic about growth despite COVID-19 challenges.
STRATA Skin Sciences, a medical technology company focused on dermatology, announced its participation in several upcoming investor conferences. Dr. Dolev Rafaeli and CFO Matthew Hill will present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 2:30 PM ET (virtual format), and the Oppenheimer MedTech Summit on the same day with 1x1 meetings. They will also attend the A.G.P. Virtual Healthcare Symposium on November 19, 2020, also focusing on 1x1 meetings. STRATA is known for its innovative XTRAC® excimer laser treatment technology, targeting skin conditions affecting over 35 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) will release its third quarter financial results on November 10, 2020, prior to market opening. A conference call is scheduled for 8:30 AM ET to discuss the results and provide a corporate update. STRATA focuses on innovative dermatological treatments, including the XTRAC excimer laser system, which targets conditions like psoriasis and vitiligo. The Company has established a robust network of over 789 dermatology clinics, enhancing patient access to reimbursable treatment options.
STRATA Skin Sciences (NASDAQ: SSKN) announced a peer-reviewed study in the Journal of Drugs in Dermatology highlighting the cost-effectiveness and clinical efficacy of its XTRAC excimer laser for psoriasis. The study reveals that XTRAC provides faster results with fewer adverse events compared to traditional treatments, achieving up to 97% savings over biologic drugs. Patients experience shorter treatment durations and can attain remission without maintenance therapy. The results position XTRAC as a valuable alternative amid rising concerns over costly biologic therapies.
STRATA Skin Sciences announced that Cigna now covers excimer laser therapy for treating localized vitiligo, previously deemed cosmetic. The policy allows for up to 12 weeks of treatment, with extensions possible based on clinical response. This change could significantly expand the market for STRATA, as approximately $38,000 can be reimbursed per patient over a year. The company highlights its unique position, being the sole licensee of vitiligo-related patents, and aims to reach more dermatology clinics and patients across the U.S.
STRATA Skin Sciences announced a new direct distribution contract with JMEC Co., Ltd. for its XTRAC® and VTRAC® products in Japan. This contract aims to enhance brand value, leveraging STRATA's strong balance sheet and JMEC's distribution network. With over 12,000 dermatologists in Japan, STRATA expects recurring revenue impacts by the end of 2020. The treatment procedure covered by national health insurance is priced at $33. The partnership builds on a 15-year relationship to expand treatment access for vitiligo and psoriasis patients in a growing market.
STRATA Skin Sciences (NASDAQ: SSKN) will release its second quarter financial results for the period ended June 30, 2020, on August 11 before market open. The company focuses on innovative products for dermatological conditions, with a primary offering being the XTRAC excimer laser system. This technology addresses conditions like psoriasis and vitiligo, impacting over 35 million patients in the U.S. STRATA has established a network of over 822 clinics and more than 2,000 devices worldwide, utilizing a direct-to-consumer advertising model to drive awareness and increase physician introductions.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
